1
Participants
Start Date
September 11, 2024
Primary Completion Date
February 18, 2025
Study Completion Date
February 18, 2025
NP137
IV infusion, 14mg/kg or 9mg/kg, every 2 weeks
Azacitidine Injection
Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)
Venetoclax
Orally, 70 mg, every day on Days 1-28
Centre Léon Bérard, Lyon
Collaborators (1)
NETRIS Pharma
INDUSTRY
Centre Leon Berard
OTHER